CRISPR Therapeutics Reports Strong CASGEVY Growth, Expands Pipeline
Event summary
- CASGEVY generated $116 million in 2025 revenue, up from prior periods, with 64 patients treated.
- Patient initiations for CASGEVY increased nearly three-fold in 2025 compared to 2024.
- CRISPR Therapeutics advanced multiple in vivo gene editing programs, including CTX310, CTX321, and CTX460.
- The company reported a net loss of $130.6 million for Q4 2025, up from $37.3 million in Q4 2024.
- CRISPR Therapeutics expects to initiate clinical trials for CTX460 and CTX340 in mid-2026.
The big picture
CRISPR Therapeutics continues to solidify its position as a leader in gene editing, with CASGEVY driving significant revenue growth and patient uptake. The company's expanding pipeline in cardiovascular, autoimmune, and oncology indications reflects broader industry trends toward precision medicine and gene-based therapies. Strategic collaborations with Vertex and Sirius Therapeutics further enhance its capabilities, but managing financial performance amid high R&D investments remains a challenge.
What we're watching
- Regulatory Approvals
- The pace at which CRISPR Therapeutics secures regulatory approvals for pediatric indications of CASGEVY will impact its market expansion.
- Pipeline Progress
- Whether CRISPR Therapeutics can sustain momentum in its diverse pipeline, particularly in autoimmune disease and oncology, will be critical for long-term growth.
- Financial Performance
- How CRISPR Therapeutics manages its increasing R&D and collaboration expenses against revenue growth from CASGEVY will be a key focus for investors.
Related topics